1995
The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents.
Deisseroth A, DeVita V. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. The Cancer Journal 1995, 1: 15-21. PMID: 9166447.Peer-Reviewed Original ResearchConceptsMolecular determinants of resistanceNormal tissuesSensitivity to cytotoxic agentsConventional dose therapyTherapy-induced side effectsIntroduction of chemotherapyCurative therapeutic interventionParadigm of treatmentPresence of mutationsCells to treatmentDose therapyBiologic therapySolid tumorsDeterminants of resistanceHematopoietic neoplasmsChemotherapeutic agentsChemotherapyCytotoxic agentsNeoplastic cellsSide effectsTherapyApplication of molecular analysisTherapeutic interventionsCell deathNeoplasms
1981
Animal toxicology for early clinical trials with anticancer agents.
Rozencweig M, Von Hoff D, Staquet M, Schein P, Penta J, Goldin A, Muggia F, Freireich E, DeVita V. Animal toxicology for early clinical trials with anticancer agents. American Journal Of Clinical Oncology 1981, 4: 21-8. PMID: 6783332.Peer-Reviewed Original ResearchConceptsPhase I clinical trialEarly clinical trialsClinical trialsOrgan system toxicityStarting doseSystem toxicityChemotherapeutic agentsDose-escalation stepsCommon toxic effectsGastrointestinal intoleranceInitial doseClinical dataEscalation stepsAnimal findingsToxic doseToxic manifestationsIndividual drugsPredictive valueAnimal toxicologyMiceDoseIdentical scheduleLD10Acceptable dosesDogs
1971
Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU
Young R, DeVita V, Serpick A, Canellos G. Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU. New England Journal Of Medicine 1971, 285: 475-479. PMID: 5558887, DOI: 10.1056/nejm197108262850902.Peer-Reviewed Original Research